One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration (FDA) for its lead asset, inebilizumab.
{iframe}https://www.biospace.com/article/interview-viela-bio-eyes-bla-for-lead-asset-only-one-year-after-launch/{/iframe}